Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia Meeting Abstract
| Authors: | King, A. C.; Pappacena, J.; Tallman, M. S.; Park, J. H.; Geyer, M. B. |
| Abstract Title: | Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia |
| Meeting Title: | 60th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 132 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Dec 1-4 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2018-11-29 |
| Language: | English |
| ACCESSION: | WOS:000454837604085 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood-2018-99-113162 |
| Notes: | Meeting Abstract: 1414 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
